FDAnews
www.fdanews.com/articles/172795-veritas-receives-ce-mark-approval-for-hereditary-breast-and-ovarian-cancer-screening-test

Veritas Receives CE Mark Approval for Hereditary Breast and Ovarian Cancer Screening Test

August 26, 2015

Veritas Genetics received CE mark approval for its breast and ovarian cancer genetic screening test, myBRCA, which sequences the BRCA1 and BRCA2 genes using proprietary gene-targeting technology and next generation sequencing.

According to Veritas, studies show that around 50 percent of women with BRCA1 and BRCA2 mutations have no substantial family history of breast and ovarian cancer, and that harmful mutations in these genes represent a lifetime risk of up to 80 percent for breast cancer and up to 40 percent for ovarian cancer.

Preston Estep III, founder and chief scientific officer of Veritas and director of gerontology for the Personal Genome Project at Harvard Medical School, says the affordable, saliva-based test and its database will make genetic information accessible globally to promote informed decision making and disease prevention. — Michael Cipriano